Filing Flows › Immunome (IMNM) › R&D spending
Immunome (IMNM) R&D spending by quarter
Immunome's R&D spending was $40.5M in Q2 2025 (second quarter 2025), +10% from Q1 2025. Over the last 3 quarters it ranged from $36.9M (Q1 2025) to $47.9M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2025 | $40.5M | +10% | — |
| Q1 2025 | $36.9M | -23% | — |
| Q4 2024 | $47.9M | — | — |
Q2 2025 at a glance
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immunome's R&D spending?
Immunome's R&D spending was $40.5M in Q2 2025 (second quarter 2025), +10% from Q1 2025.
How has Immunome's R&D spending changed?
Over the last 3 quarters it ranged from $36.9M (Q1 2025) to $47.9M (Q4 2024).